Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer
Paul Sabbatini, MD
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.
Dose-dense therapy or every-3-week therapy allows for many additional combinations in the primary setting, explains Sabbatini. Adding PARP inhibitors, maintenance therapy, anti-vascular agents, or other novel compounds are currently being investigated.
According to Sabbatini, it would be difficult to incorporate those into an IP with cisplatin.